Reversing Multidrug Resistance with Nifedipine and Etoposide
Author Information
Author(s): P.A. Philip, S. Joel, S.C. Monkman, E. Dolega-Ossowski, K. Tonkin, J. Carmichael, J.R. Idle, A.L. Harris
Primary Institution: ICRF Clinical Oncology Unit, Churchill Hospital, Oxford
Hypothesis
Can nifedipine reverse multidrug resistance (MDR) in patients receiving etoposide?
Conclusion
The study found that the maximum tolerated dose of nifedipine was 60 mg twice daily, but it did not significantly alter the pharmacokinetics of etoposide.
Supporting Evidence
- Nifedipine was administered at three dose levels: 40 mg, 60 mg, and 80 mg.
- Patients had various malignancies including renal cell carcinoma and breast carcinoma.
- Severe headaches and postural hypotension were noted as dose-limiting side effects.
Takeaway
This study tested a drug called nifedipine to see if it could help another drug, etoposide, work better against cancer. They found a safe dose of nifedipine, but it didn't change how well etoposide worked.
Methodology
Fifteen patients with various malignancies received nifedipine at three dose levels and etoposide was administered intravenously and orally.
Potential Biases
Potential bias due to the small number of participants and lack of a control group.
Limitations
The study had a small sample size and did not assess long-term effects.
Participant Demographics
Nine males and six females with a mean age of 46.2 years.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website